Introduction {#s0005}
============

Alzheimer\'s disease (AD) is an increasingly prevalent problem as the population ages. Structural MR imaging is a well established, widely available, non-invasive tool for investigating the inevitable downstream consequence of neurodegeneration in Alzheimer\'s disease---atrophy. In the correct clinical context the presence of medial temporal lobe atrophy on cross-sectional MR imaging has positive predictive value for a diagnosis of AD and this is now incorporated in diagnostic criteria ([@bb0080; @bb0145]). Quantification of the rate of global and regional brain volume loss from serially acquired MRI is increasingly used both to understand the progression of the disease and as an outcome measure for clinical trials, with the premise that a disease-modifying therapy would be expected to slow the rate of atrophy towards that seen in normal ageing ([@bb0095]). Numerous methods for quantifying change between serial scans have been proposed and are used both in observational and therapeutic studies. In the absence of a "gold standard" validating new methods and comparing the performance of different algorithms are not straightforward.

We announce here the public release of a longitudinal database of structural (T1 contrast) MRI scans from the Minimal Interval Resonance Imaging in Alzheimer\'s Disease (MIRIAD) study. Whilst there are a number of other open imaging databases, including the Alzheimer\'s Disease Neuroimaging Initiative (ADNI, [@bb0120]), the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL, [@bb0085]) and Open Access Series of Imaging Studies (OASIS, [@bb0135]) the MIRIAD dataset has a number of features making it ideal for methods development and validation. These include:1.all scans on the same scanner over the same time period;2.multiple serial scans (up to nine over two years) for both AD and controls;3.a scanning schedule designed to give a wide range of inter-scan intervals from 2 weeks to 2 years; and4.back-to-back scanning at three time points.

These features allow for formal assessments of the symmetry, transitivity and reproducibility of measures of atrophy, and assessment of bias ([@bb0100]). By making this dataset widely available, the performance of different image analyses methodologies can be compared directly; and novel tools can be validated before being applied to other datasets.

Overview {#s0010}
========

The MIRIAD study was principally motivated to establish the minimal interval over which it would be feasible to undertake clinical trials in Alzheimer\'s disease using atrophy measured from serial MRI as an outcome measure. Supplementary aims were:1.To assess whether combining more than two scanning time points would increase statistical power and, if so, the optimal combination and timing of scans for trials of varying lengths.2.To provide a means of assessing the reproducibility of techniques within a single day and over short intervals where changes in individual\'s hydration and scanner fluctuations, but not pathological atrophy, might be expected.

Details of subject demographics have been previously described ([@bb0165]) and are summarised here in [Table 1](#t0005){ref-type="table"}. In brief the dataset includes 46 patients with a diagnosis of mild--moderate probable AD (NINCDS--ADRDA, [@bb0140]) all seen at the Dementia Research Centre, Institute of Neurology, UCL, and 23 non-demented control subjects, typically the patient\'s spouse or carer. Inclusion criteria included age over 55 years and a mini-mental state examination (MMSE, [@bb0090]) score between 12 and 26/30. Controls had MMSE scores \> 26/30, and no history of cognitive impairment, head injury, major psychiatric disease or stroke. Exclusion criteria included any neurodegenerative disease (apart from AD for the patients), or inability to tolerate MRI. At baseline and one year all subjects underwent a detailed neuropsychometric and clinical evaluation. MMSE score was recorded at baseline and 6-monthly intervals. All subjects were requested to attend seven imaging visits at 0, 2, 6, 14, 26, 38 and 52 weeks from baseline. 39 subjects who completed all these visits during the study attended a further scan at 18 months, 22 of these had a further scan at 24 months. At 0, 6 and 38 weeks two back-to-back scans were conducted. Study attendance figures are shown in [Table 2](#t0010){ref-type="table"}. Ethical approval for the study (and subsequently its release) was received from the local research ethics committee, and written consent obtained from all participants.

All scans were conducted on the same 1.5 T Signa MRI scanner (GE Medical systems, Milwaukee, WI) and acquired by the same radiographer. Three-dimensional T1-weighted images were acquired with an IR-FSPGR (inversion recovery prepared fast spoiled gradient recalled) sequence, field of view 24 cm, 256 × 256 matrix, 124 1.5 mm coronal partitions, TR 15 ms, TE 5.4 ms, flip angle 15°, TI 650 ms. A total of 708 volumetric scans were acquired with up to 12 scans per individual, 25 different interscan intervals, allowing for a total of 2199 scan-pairs for patients with AD and 1182 scan-pairs for controls.

Results to date {#s0015}
===============

A list of published articles which have used (in full or in part) this dataset is shown in [Table 3](#t0015){ref-type="table"}. Amongst others, these have included a number of methodological papers describing techniques for estimating hippocampal atrophy using a hippocampal template and the boundary shift integral ([@bb0015]), fluid registration ([@bb0020]), an automated medial temporal lobe scale ([@bb0155]) and label fusion methods ([@bb0125]). Clinical papers have included assessments of hippocampal asymmetry in AD ([@bb0010]); the effect of APOE status on cortical thickness ([@bb0115]); the correlation between rate of atrophy and change in certain neuropsychological test scores ([@bb0170]); and the demonstration that the use of affine image registration (nine degrees of freedom) can correct for longitudinal changes in voxel size ([@bb0185]). These data have been used to compare methods for automated calculation of volumes and atrophy in the hippocampus ([@bb0025]), and atrophy measured using the boundary shift integral with both Jacobian integration ([@bb0040]), and with both SIENA and SIENAX ([@bb0180]). For clinical trials, the MIRIAD dataset has been used to estimate required sample sizes for six-month AD clinical trials using ventricular expansion ([@bb0160]) and hippocampal atrophy ([@bb0025]) as outcome measures; and using grey matter atrophy ([@bb0005]). Using a multi-level model specifically designed to analyse this data-set ([@bb0105; @bb0165]) provided a detailed assessment of the mean whole brain rate of atrophy (2.23%/year, 95% CI: 1.90--2.56%/year using the boundary shift integral implementation at that time) and between- and within-subject sources of variance in atrophy in AD trials (total variance 0.99^2^ + (0.82/*t*)^2^, from 2 scans '*t*' years apart). Using these results they estimated sample sizes required to power AD studies over intervals of 6, 12, and 24 months (with and without drop-outs) using between 2 and 5 scanning time points spaced either evenly or optimally. This model was subsequently extended to estimate whether estimating brain atrophy from a run-in period could increase efficiency for clinical trials ([@bb0110]).

Data release {#s0020}
============

For the purposes of this data-release scans were converted from DICOM to NIfTI-1 format using MRICron/dcm2nii[1](#fn0005){ref-type="fn"} and all identifiable information removed in the process. Subjects were assigned a random identifier and the NIfTI files with a subject and visit identifier were placed in an Extensible Neuroimaging Archive Toolkit (XNAT, [@bb0130]) database. An archive containing all the images was also prepared and placed on the XNAT system. For those visits where MMSE scores were collected this information is also available. The full dataset and terms of use will be available at <http://miriad.drc.ion.ucl.ac.uk/> from Friday 8th February 2013.

Discussion {#s0025}
==========

We hope that the release of this dataset will provide the imaging community---and particularly those interested in the accurate quantification of volume change from serially acquired MR---with a useful common resource with which techniques can be developed, validated and compared, prior to implementation on other datasets or for clinical trials. Towards this goal this dataset has already been used in a blinded form as part of the Medical Image Computing and Computer Assisted Intervention (MICCAI) 2012 challenge "Atrophy Measurement Biomarkers using Structural MRI for Alzheimer\'s Disease".[2](#fn0010){ref-type="fn"} The release of this dataset in an open form (together with the blinding codes from the MICCAI challenge) will enable other workers to compare their methods to workshop outcomes on the same dataset.

This dataset is made available through the support of the UK Alzheimer\'s Society. The original data collection was funded through an unrestricted educational grant from GlaxoSmithKline and funding from the UK Alzheimer\'s Society (to Dr Schott) and the Medical Research Council (to Professor Fox). Professor Ourselin receives funding from the EPSRC (EP/H046410/1) and the Comprehensive Biomedical Research Centre (CBRC) Strategic Investment Award (Ref. 168). Dr Ridgway is supported by the Medical Research Council \[grant number MR/J014257/1\]. This work was supported by the National Institute for Health Research (NIHR) Biomedical Research Unit in Dementia based at University College London Hospitals (UCLH), University College London (UCL). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The Dementia Research Centre is an Alzheimer\'s Research UK (ARUK) Coordinating Centre. The Wellcome Trust Centre for Neuroimaging is supported by core funding from the Wellcome Trust \[grant number 091593/Z/10/Z\].

We are grateful to the funders for their willingness to share these data.

<http://www.nitrc.org/projects/mricron>.

<http://picsl.upenn.edu/Miccai2012/Challenge>.

###### 

Demographics of the dataset.

  -----------------------------------------------------------------
                               Alzheimer\'s Disease\   Controls\
                               (N = 46)                (N = 23)
  ---------------------------- ----------------------- ------------
  Age at study entry (years)   69.4 ± 7.1              69.7 ± 7.2

  Men                          41 (%)                  52 (%)

  Mean (SD) baseline MMSE      19.2 ± 4                29.4 ± 0.8
  -----------------------------------------------------------------

###### 

Timing and attendance of visits.

  ----------------------------------- ------ ------ ------ ------ ------
  Mean interval days from baseline\   0      16\    43\    98\    180\
  (SD)                                       (5)    (6)    (8)    (7)

  Subjects (patients) scanned         68\    66\    67\    68\    66\
                                      (45)   (44)   (45)   (46)   (44)

  Scans completed                     133    66     130    68     66

                                                                  

  Mean interval days from baseline\   270\   365\   552\   730\   
  (SD)                                (19)   (14)   (18)   (10)   

  Subjects (patients) scanned         60\    67\    39\    22\    
                                      (38)   (44)   (26)   (14)   

  Scans completed                     117    67     39     22     
  ----------------------------------- ------ ------ ------ ------ ------

###### 

Publications featuring MIRIAD data.

  --------------------------------- ----------------------
  *Atrophy in dementia*             
  [@bb0040]                         NeuroImage
  [@bb0115]                         Dement Geriatr Cogn
  [@bb0150]                         NeuroImage
  [@bb0070]                         MICCAI 2009
  [@bb0005]                         Neurobiol Aging
                                    
  *Medial--temporal lobe atrophy*   
  [@bb0010]                         Dement Geriatr Cogn
  [@bb0015]                         Neurobiol Aging
  [@bb0020]                         J Comput Assist Tomo
  [@bb0155]                         Arch Neurol-Chicago
  [@bb0025]                         NeuroImage
  [@bb0030]                         Neurobiology
  [@bb0035]                         NeuroImage
  [@bb0125]                         NeuroImage
                                    
  *Simulation studies*              
  [@bb0175]                         MICCAI 2005
  [@bb0060]                         MICCAI 2006
  [@bb0045]                         IEEE T Med Imaging
  [@bb0065]                         MICCAI 2006
  [@bb0050]                         MICCAI 2007
  [@bb0055]                         NeuroImage
                                    
  *Clinical trials design*          
  [@bb0185]                         Magn Reson Imaging
  [@bb0160]                         Neurology
  [@bb0165]                         J Neurol
  [@bb0110]                         Stat Med
  [@bb0170]                         Neuropsychologia
                                    
  *Methods comparison*              
  [@bb0180]                         NeuroImage
  [@bb0075]                         NeuroImage
  --------------------------------- ----------------------
